Raymond K. Cross, MD, MS, AGAF, FACG, professor of medicine and director of the IBD Program, University of Maryland School of Medicine, discusses the positioning of therapies for irritable bowel syndrome. He discusses the treat-to-target approach for monitoring disease activity and the factors that should be considered for positioning highly effective therapy. Dr Cross also discusses treatments, such as ustekinumab, vedolizumab, and adalimumab.